A rapidly growing body of data suggests that dysfunction in serotonergic (5-HT) function may
be involved in the pathophysiology of schizophrenia, and that pharmacologic agents for this …

Background The purpose of this investigation was to test the efficacy of novel antipsychotic
medications in the treatment of cognitive impairment in early phase schizophrenia. Methods …

Several serious questions exist regarding the diagnostic classification of anxiety disorders.
The authors examine the diagnostic validity of generalized anxiety disorder and panic …

Cognitive impairment is a central feature of schizophrenia and has been correlated with
negative symptoms and impaired social functioning. There is a growing body of data suggesting …

A major line of evidence that supports the hypothesis of dopamine overactivity in schizophrenia
is the psychomimetic potential of agents such as amphetamine that stimulate dopamine …

The authors present the findings from a long-term follow-up study of 118 patients from
Vermont State Hospital who, when rediagnosed retrospectively, met DSM-lll criteria for …

Background Despite the longer duration of the depressive phase in bipolar disorder and the
frequent clinical use of antidepressants combined with antipsychotics or mood stabilizers, …

• We performed a longitudinal study of chronic schizophrenic patients who were hospitalized
for research purposes at the National Institute of Mental Health (NIMH) Intramural Program …

The authors report the latest findings from a 32-year longitudinal study of 269 back-ward
patients from Vermont State Hospital. This intact cohort participated in a comprehensive …

A rapidly growing body of preclinical data has implicated the glutamatergic N-methyl-d-aspartate
(NMDA) receptor in memory and other cognitive processes. There is comparatively less …